Skip to main content
. 2017 Dec 8;9(4):4661–4674. doi: 10.18632/oncotarget.23163

Figure 6.

Figure 6

(A) Expression of miR-1, FRAS1, miR-663a and MDGA1 in control, sunitinib sensitive and resistant xenografts. (B) Experimental validation of miR-1-FRAS1 interaction. miR-1 overexpression was able to significanly reduce the level of FRAS1 at both mRNA (measured by qRT-PCR, the two left graphs) and protein (assessed by western blot, the right graph) levels. (C) Experimental validation of the ability of miR-663a to target MDGA1. miR-663a over expression was able to significanly reduce the level of MDGA1 mRNA (qRT-PCR analysis, left) and protein (western blot analysis, right). (D) siRNA resulted in decreased MDGA1 protein expression (western blot). MDGA1 knock-down resulted in significant reduction of the rate of cell proliferation and migration (wound healing assay). (E) Transfection of miR-1 and miR-663a mimics led to decreased cell migration but had no effect on proliferation.